Milk-Derived Peptides Selectively Kill Cancer Cells by Targeting a Cancer-Specific Membrane Marker
Engineered di-peptides derived from human lactoferricin achieved up to 100% cancer cell killing at 20 μM by specifically targeting phosphatidylserine on cancer cell membranes, with 10-fold greater melanoma toxicity than the parent peptide.
Quick Facts
What This Study Found
Di-peptide and di-retro-peptide derivatives of human lactoferricin (hLFcin) achieved up to 100% cancer cell toxicity at 20 μM concentration across melanoma (A375), glioblastoma (U-87mg), and rhabdomyosarcoma cell lines. Compared to the parent hLFcin sequence, derivatives showed 10-fold increased toxicity on melanoma and 2-3-fold on glioblastoma.
Structural analysis revealed a critical insight: peptides with loop structures selectively killed cancer cells via apoptosis (confirmed by caspase 3/7 activation, apoptotic blebbing, and DNA fragmentation), while peptides with α-helical structures without loops killed non-specifically through rapid membrane lysis (necrosis). Phosphatidylserine — uniquely exposed on cancer cell surfaces — was identified as the primary membrane target for cancer-selective peptides. Other negatively charged molecules (sialic acid, heparan/chondroitin sulfate) had minor impact on activity.
Key Numbers
How They Did This
Researchers designed multiple lactoferricin-derived peptides of 9-11 amino acids, then created di-peptide (repeated) and di-retro-peptide (retro-repeated) versions. These were tested against melanoma (A375), glioblastoma (U-87mg), and rhabdomyosarcoma cancer cell lines and compared with normal cells. Cell killing was assessed by viability assays. Apoptosis was confirmed through caspase 3/7 activation, membrane blebbing, and DNA fragmentation analysis. Peptide structures were characterized by circular dichroism. Membrane interactions were studied using phosphatidylserine model membranes and differential scanning calorimetry.
Why This Research Matters
Cancer-selective killing is the holy grail of oncology — destroying tumors while sparing healthy tissue. This study identifies a clear structural rule: loop-shaped peptides target cancer-specific phosphatidylserine and trigger clean apoptotic death, while helical peptides cause nonselective damage. This provides a rational design framework for building peptide-based cancer drugs from naturally derived milk protein fragments, potentially offering a new class of targeted cancer therapeutics with fewer side effects than chemotherapy.
The Bigger Picture
Lactoferricin is an antimicrobial peptide released from lactoferrin in breast milk during digestion. The discovery that its derivatives can selectively kill cancer cells represents a fascinating connection between innate immunity and anti-cancer defense. Phosphatidylserine targeting has become a hot area in oncology, with several companies developing PS-targeted therapies. These lactoferricin derivatives offer a unique approach: natural-origin peptides that exploit a cancer-specific vulnerability, potentially combining the selectivity of targeted therapy with the membrane-disrupting power of antimicrobial peptides.
What This Study Doesn't Tell Us
This is entirely an in vitro study using cancer cell lines, which do not capture the complexity of tumors growing in living tissue with blood supply, immune cells, and microenvironment. The peptides' stability in blood, ability to reach tumors, and effects on normal tissues in vivo are unknown. The 20 μM concentration needed for 100% killing may be difficult to achieve at tumor sites. Only three cancer types were tested. Long-term toxicity and immunogenicity were not assessed.
Questions This Raises
- ?Can these lactoferricin di-peptides reach tumor sites at therapeutic concentrations when administered systemically in animal models?
- ?Would the cancer-selective loop peptides work against a broader range of cancer types that expose phosphatidylserine?
- ?Could these peptides be combined with existing cancer immunotherapies to enhance tumor killing?
Trust & Context
- Key Stat:
- 10× more potent on melanoma The engineered di-peptide derivatives achieved 10-fold greater melanoma killing than the parent lactoferricin peptide, with cancer selectivity driven by loop structure targeting phosphatidylserine
- Evidence Grade:
- This is a preclinical in vitro study using cancer cell lines and membrane model systems. While the mechanistic findings are detailed and the structure-activity relationships are well-characterized, all results need validation in animal models before clinical relevance can be assessed.
- Study Age:
- Published in 2015, this study established important structure-activity principles for cancer-selective lactoferricin peptides. The PS-targeting approach has continued to develop in the decade since, with ongoing research into peptide-based anti-cancer strategies.
- Original Title:
- Human lactoferricin derived di-peptides deploying loop structures induce apoptosis specifically in cancer cells through targeting membranous phosphatidylserine.
- Published In:
- Biochimica et biophysica acta, 1848(11 Pt A), 2918-31 (2015)
- Authors:
- Riedl, Sabrina(3), Leber, Regina(2), Rinner, Beate(3), Schaider, Helmut, Lohner, Karl, Zweytick, Dagmar
- Database ID:
- RPEP-02778
Evidence Hierarchy
Frequently Asked Questions
Why can peptides from breast milk kill cancer cells?
Lactoferricin is an antimicrobial peptide released from the milk protein lactoferrin. It evolved to kill bacteria by disrupting their membranes. Cancer cells share a feature with bacteria: they expose a molecule called phosphatidylserine (PS) on their outer membrane, while healthy human cells keep it hidden inside. This makes cancer cells vulnerable to membrane-targeting peptides that recognize PS, essentially exploiting the same vulnerability that bacteria have.
What makes some peptides kill only cancer cells while others kill everything?
The key difference is shape. Peptides with loop structures interact specifically with phosphatidylserine on cancer cell membranes and trigger orderly programmed cell death (apoptosis). Peptides with alpha-helix structures insert more aggressively into any membrane and cause rapid, nonselective cell rupture (necrosis). By engineering peptides with the right loop structure, researchers can create cancer-selective killers that leave healthy cells largely unharmed.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-02778APA
Riedl, Sabrina; Leber, Regina; Rinner, Beate; Schaider, Helmut; Lohner, Karl; Zweytick, Dagmar. (2015). Human lactoferricin derived di-peptides deploying loop structures induce apoptosis specifically in cancer cells through targeting membranous phosphatidylserine.. Biochimica et biophysica acta, 1848(11 Pt A), 2918-31. https://doi.org/10.1016/j.bbamem.2015.07.018
MLA
Riedl, Sabrina, et al. "Human lactoferricin derived di-peptides deploying loop structures induce apoptosis specifically in cancer cells through targeting membranous phosphatidylserine.." Biochimica et biophysica acta, 2015. https://doi.org/10.1016/j.bbamem.2015.07.018
RethinkPeptides
RethinkPeptides Research Database. "Human lactoferricin derived di-peptides deploying loop struc..." RPEP-02778. Retrieved from https://rethinkpeptides.com/research/riedl-2015-human-lactoferricin-derived-dipeptides
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.